StockGuru Trade Alert: New Profile Oncolin Therapeutics (OCOL) Up More than 33% Intraday and More than 48% Since Tuesday
Based on Today’s Intraday High of $0.40 Our New Profile OCOL is Up More than 33% Today
Tuesday’s Close: $0.27
Wednesday’s Close: $0.30
Today’s High $0.40
And OCOL is Up More than 48% Since Tuesday’s Close!
View the StockGuru Profile for OCOL:
http://www.stockguru.com/profiles/ocol/
About Oncolin Therapeutics: Oncolin Therapeutics, Inc. (OTCBB: OCOL) is a biopharmaceutical company focused on developing drugs which interfere with the key mechanisms of cancer tumor development. The company engages in the discovery, development and commercialization of novel selective anticancer therapies. The company has a lead drug for brain cancer in preclinical development licensed from the MD Anderson Cancer Center. Oncolin is focused on the development of this drug to clinical development with an IND scheduled to be filed in approximately 18 months [ Investigational New Drug (application to the FDA) ]. The company also has a robust pipeline of oncology research programs that are mainly funded by Federal grants.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 10604 Robincreek Lane, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Pentony Enterprises LLC has been compensated $12,000 from a non-controlling third party for profile coverage. Previously we have been compensated $25,400 from a non-controlling third party.Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.� Oncolin Therapeutics, Inc. (OTCBB: OCOL) is a biopharmaceutical company focused on developing drugs which interfere with the key mechanisms of cancer tumor development. The company engages in the discovery, development and commercialization of novel selective anticancer therapies. The company has a lead drug for brain cancer in preclinical development licensed from the MD Anderson Cancer Center. Oncolin is focused on the development of this drug to clinical development with an IND scheduled to be filed in approximately 18 months [ Investigational New Drug (application to the FDA) ]. The company also has a robust pipeline of oncology research programs that are mainly funded by Federal grants.